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A systematic literature review and meta-analysis were conducted to estimate the antibacterial treatment effect for linezolid and
ceftaroline to inform on the design of acute bacterial skin and skin structure infection (ABSSSI) noninferiority trials. The pri-
mary endpoints included an early clinical treatment response (ECTR) defined as cessation of lesion spread at 48 to 72 h postran-
domization and the test-of-cure (TOC) response defined as total resolution of the infection at 7 to 14 days posttreatment. The
systematic review identified no placebo-controlled trials in ABSSSI, 4 placebo-controlled trials in uncomplicated skin and soft
tissue infection as a proxy for placebo in ABSSSI, 12 linezolid trials in ABSSSI, 3 ceftaroline trials in ABSSSI, and 2 trials for non-
antibacterial treatment. The ECTR rates at 48 to 72 h and corresponding 95% confidence intervals (CI) were 78.7% (95% CI, 61.1
to 96.3%) for linezolid, 74.0% (95% CI, 69.7 to 78.3%) for ceftaroline, and 59.0% (95% CI, 52.8 to 65.3%) for nonantibacterial
treatment. The early clinical treatment effect could not be estimated, given no available placebo or proxy for placebo data for this
endpoint. Clinical, methodological, and statistical heterogeneity influenced the selection of trials for the meta-analysis of the
TOC treatment effect estimation. The pooled estimates of the TOC treatment response were 31.0% (95% CI, 6.2 to 55.9%) for the
proxy for placebo, 88.1% (95% CI, 81.0 to 95.1%) for linezolid, and 86.1% (95% CI, 83.7 to 88.6%) for ceftaroline. The TOC clini-
cal treatment effect estimation was 25.1% for linezolid and 27.8% for ceftaroline. The antibacterial treatment effect estimation at
TOC will inform on the design and analysis of future noninferiority ABSSSI clinical trials.
Over the past decade, robust clinical, scientific, and regulatorydebate has emerged for initiatives to improve the design, ex-
ecution, and analysis of antibacterial clinical trials (1–4). New tri-
als for acute bacterial skin and skin structure infections (ABSSSI),
previously referred to as complicated skin and skin structure in-
fections (cSSTI), remain important, given the rise in incidence of
methicillin-resistant Staphylococcus aureus infections and reports
of treatment failure (5–8). Per guidance from the U.S. Food and
Drug Administration (FDA), patient eligibility for enrollment in
ABSSSI trials should be restricted to those with erysipelas, celluli-
tis, major cutaneous abscesses, and wound infections having a
minimal lesion surface area involvement of 75 cm2 (9). For trial
endpoints, the traditional test-of-cure (TOC) endpoint, with the
treatment success defined as total resolution of the infection at 7 to
14 days posttreatment, remains aligned with the European regu-
latory guidance, yet the treatment success for the primary efficacy
endpoint aligned with the FDA guidance is defined as cessation of
lesion spread after 48 to 72 h of treatment (9–11). Revisions to the
enrollment and endpoint criteria in recent regulatory guidance for
ABSSSI trials necessitate reevaluation of the antibacterial treat-
ment effect estimation calculated from across-trials comparisons
of existing data for noninferiority trial design (4, 12–16).
To inform on future noninferiority ABSSSI trial design, we
conducted a systematic review and meta-analysis of antibacterial
treatment effect estimation. Linezolid and ceftaroline were a priori
selected as drugs representative of potential active comparators
for hospitalized adults with ABSSSI in a global phase 3 clinical
development program. The trial data extracted for the systematic
review were aligned with regulatory guidance for the enrollment
and endpoint criteria in ABSSSI trials. A predefined meta-analysis
plan defined the efficacy variables, primary endpoints of interest,
and computational methods for antibacterial treatment effect es-
timation in ABSSSI historical trials for noninferiority margin jus-
tification.
MATERIALS AND METHODS
Study design. The systematic review and meta-analysis were designed and
executed in compliance with the Preferred Reporting Items for Systematic
Reviews and Meta-Analysis (PRISMA) (17–19). Two independent re-
viewers conducted computer-based literature searches and a systematic
review using the MEDLINE search engine (PubMed, U.S. National Li-
brary of Medicine, National Institutes of Health; http://www.ncbi.nlm
.nih.gov). Ideally, treatment effect estimation for a noninferiority antibac-
terial trial should be calculated from placebo-controlled trials to allow for
within-trial comparison of the antibacterial treatment response com-
pared to the placebo treatment response (11, 14). Given a prior report that
placebo-controlled trials were nonexistent for complicated skin infections
(20), we partitioned the literature searches to identify placebo-controlled
trials of any antibacterial treatment for ABSSSI (Appendix, search A1) as
well as randomized clinical trials of active comparators in ABSSSI for
linezolid (search B1) and ceftaroline (search B2). Due to nomenclature
changes over time, studies that assessed ABSSSI, complicated skin and soft
tissue infections (cSSTI), or complicated skin and skin structure infec-
tions (cSSSI) were included. While it was previously reported that there
were no historical data for placebo-controlled trials of any antibacterial
treatment in complicated skin infections, our search strategy, by design,
would have captured any placebo-controlled ABSSSI trials, inclusive of
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trials for linezolid and ceftaroline. The placebo search was extended to
include clinical trials reporting a placebo treatment response in uncom-
plicated skin and soft tissue infections (uSSTI) as a proxy for placebo in
ABSSSI (search A2). This strategy, which comprised use of a proxy for
placebo effect estimation, has been recommended in the FDA guidance
for noninferiority trials and has been used for placebo treatment effect
estimation for trials in complicated urinary tract infections (13, 21, 22).
Given that historical studies published in 1937 reported relatively high
response rates in the treatment of erysipelas with UV light, an additional
search (search C) was conducted to identify clinical trials of nonantibac-
terial treatment in uSSTI and in ABSSSI (4, 23, 24). This search was a
priori conducted to identify potentially informative data and not as a
proxy for placebo treatment response estimation.
Identification of trials and full-screen review for eligibility. For each
search, the publications were restricted to dates before 28 February 2013.
Search terms included abbreviations and plural and full-phrase versions
of the selected search terms (listed in Appendix 1) combined with Boolean
operators (AND, OR) used in succession to narrow or widen the respec-
tive searches. Two reviewers independently assessed the identified publi-
cations for trial eligibility, data quality, and efficacy data. Eligible studies
included randomized clinical trials for the respective searches of placebo-
controlled trials (search A1), active comparator trials of linezolid (search
B1) and ceftaroline (search B2) in ABSSSI, and trials of nonantibacterial
treatment in uSSTI and ABSSSI (search C). Case series, observational
studies, review papers, duplicate studies, and studies with incomplete data
were not eligible for full-text review. The publications identified in
searches A1, B1, B2, and C were excluded for one or more of the following
criteria: pediatric exclusivity, lack of reported measure of endpoints of
interest, 15% of subjects with either diabetic foot infections, animal or
human bites, necrotizing fasciitis, decubitus ulcer infection, myonecrosis
or ecthyma gangrenosum, and pooled treatment response rates for mul-
tiple infection types. Publications of uSSTI studies in search A2 were eli-
gible for full review if the report was a placebo-controlled trial in impetigo,
furunculosis, carbunculosis, folliculitis, ecthyma, erysipelas, or second-
arily infected traumatic lesions (SITL). Publications of uSSTI studies were
excluded for one of the following criteria: placebo add-on treatment, pe-
diatric exclusivity, prevention or colonization trials, or inclusion of sub-
jects with minor cutaneous abscesses treated via incision and drainage as
surgical treatment. The latter group was excluded as any potential esti-
mate of placebo effect could not be assessed independently of the surgical
treatment effect (25–27).
Primary endpoints. For the meta-analysis, the two primary endpoints
of interest were in the intention-to-treat (ITT) population and defined as
the early clinical treatment response at 48 to 72 h after randomization and
the TOC clinical treatment response. Outcome definitions of clinical suc-
cess, cure, or treatment failure were evaluated from each of the published
studies on the basis of criteria available and assessed for methodological
and clinical heterogeneity. The early clinical treatment response was de-
fined as the proportion of subjects who experienced cessation of spread or
the reduction in the total surface area of the lesion at 48 to 72 h after
randomization or after the first dose of the study drug (9). The TOC
clinical treatment response varied in definition based on the location and
year of the trial execution but was typically defined as the proportion of
subjects who experienced total resolution of all signs and symptoms of the
infection at 1 to 2 weeks after completion of the therapy (9). Studies that
incorporated improvement in the definition of success were included in
the meta-analysis, yet noted for this composite definition of success.
Treatment was divided into three broad categories: placebo (with exten-
sion to a proxy for placebo), antibacterial, and nonantibacterial treatment
for the ITT population unless otherwise noted.
Data extraction. Data were systematically extracted for general study
characteristics, which included author, publication date, study drug and
duration of therapy, active comparator, study population description,
study years, countries or regions, study centers, and outcomes. Baseline
demographic data were abstracted to assess age, gender, geographic re-
gion, proportion of baseline infection types, and lesion size when avail-
able. Methodological details were abstracted to assess randomization pro-
cedures, sequence generation, blinding in subjects and in investigators,
eligibility criteria, inclusion and exclusion criteria, subject withdrawals,
allocation concealment, primary outcome variable, secondary outcome
variable, study definitions, timing of outcome assessment (including early
clinical treatment response at 48 to 72 h after randomization and TOC
clinical treatment response), incomplete reporting of outcomes, and
other potential sources of bias.
Assessments of trial heterogeneity and publication bias. Publica-
tions reporting trials meeting the inclusion criteria were assessed for clin-
ical, methodological, and statistical heterogeneity. Clinical heterogeneity
was defined by patient selection, interventions, and outcomes, method-
ological heterogeneity was defined by study design and execution, and
statistical heterogeneity was defined as a variation in the results beyond
sampling variability (28–31). Given the qualitative decisions associated
with clinical and methodological heterogeneity, each trial meeting the
eligibility criteria was systematically assessed by each reviewer for inclu-
sion and exclusion criteria, types and distributions of skin infections, tim-
ing of the outcome assessments, treatment duration, inclusion of lesion
improvement as an indicator of success, and the proportion of subjects
with methicillin-resistant Staphylococcus aureus (MRSA) pathogens. Each
of two independent reviewers employed the Cochrane Risk of Bias Tool
for assessment of publication bias, and any potential discrepancies were
adjudicated via consensus with a third assessor (32).
Study selection for meta-analysis. Extensive clinical, methodological,
and statistical heterogeneity influenced the selection of studies included in
the meta-analysis (31). The proxy for placebo trials selected for inclusion
in the meta-analysis was restricted to studies that did not exclusively enroll
subjects with SITL, given the differential regulatory approval of antibac-
terial agents for this infection type. For the linezolid and ceftaroline trials,
selection for inclusion in the meta-analysis was based on trial parameters
in the historical data that approximated recent ABSSSI guidance to min-
imize the clinical and methodological heterogeneity of studies pooled in
the meta-analysis (9, 31). These selection criteria were trials with total
surface lesion area of 75 cm2, a non-MRSA-specific population, and
abscesses in 50% of the population. The trials reporting UV light treat-
ment response were included in the meta-analysis as pooled nonantibac-
terial treatment (20, 23, 24).
Data analysis. Pooled treatment response rates and 95% confidence
intervals (CI) were calculated for each treatment group using the
DerSimonian-Laird methodology, a noniterative, random effects model
to account for interstudy variability that utilized the metaphor package in
R software (33). This method is commonly employed in meta-analyses of
clinical trials, as it accounts for the heterogeneity of studies through a
statistical parameter that represents the interstudy variation of the trials in
the model (33). The proportion of total variation in the study estimates
that was due to interstudy statistical heterogeneity was assessed using I2
values and associated P values for trials included in the meta-analysis.
Given the small number of the proxy for placebo and active comparator
trials, meta-regression was not feasible. The indirect, across-trial compar-
isons to estimate the antibacterial treatment effect were calculated as the
difference between the lower bound of the 95% CI of the response rate
estimate for each antibacterial treatment and the upper bound of the 95%
CI of the proxy for the placebo response rate estimate (14, 21). This meth-
odology is aligned with the FDA guidance on the design of noninferiority
trials and is acknowledged for yield of intrinsically conservative noninfe-
riority margin estimates (14). Publication bias and heterogeneity were
assessed using funnel plots (34).
RESULTS
Systematic review. No placebo-controlled trials of ABSSSI were
identified (Appendix, search A1). There were 800 placebo records
for uSSTI (search A2), 477 linezolid records (search B1), 73 cef-
taroline records (search B2), and 2,390 records for trials defined as
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nonantibacterial treatments for skin infection (search C). The fi-
nal selection of publications included 4 placebo-controlled uSSTI
trials (35–38), 12 linezolid trials (39–50), 3 ceftaroline trials (51–
53), 1 retrospective ceftaroline secondary analysis (54), and 2 non-
antibacterial treatment trials of UV light for erysipelas (23, 24)
(Fig. 1).
(i) Proxy trials of uSSTI for placebo treatment of ABSSI
(searches A1 and A2). The four trials as proxy for placebo included
234 subjects with a range of uncomplicated infections reported as
impetigo, folliculitis, SITL, and pyoderma (Table 1). Publication
dates were from 1974 to 2013, three of the trials enrolled a subset
of subjects 18 years of age, and one publication required certi-
fied translation from French to English (35–38). Each trial re-
ported a TOC clinical treatment response; none reported an early
clinical treatment response.
(ii) Antibacterial trials of ABSSSI (searches B1 and B2).
Among the 12 linezolid trials published between the years 2000
and 2013, three were phase 2 trials, three restricted enrollment to
subjects with MRSA infections (44, 46, 47), three were specific to
China and the Asia-Pacific region (43, 44, 48), and one (45) re-
ported only the treatment response rate for the clinically evaluable
population (Table 1). The ceftaroline publications included one
phase 2 trial, two registrational phase 3 trials, and a secondary
subset analysis of the two phase 3 CANVAS (ceftaroline versus
vancomycin in skin and skin structure infections) trials reporting
an early clinical treatment response (51–54).
(iii) Nonantibacterial treatment trials (search C). The open-
label controlled trials of subjects with erysipelas compared UV
light to either prontosil or sulfanilamide (23, 24). The clinical data
available did not specify lesion size, yet provided descriptive data
for severely ill subjects with erysipelas and endpoints aligned with
an early clinical treatment response at 48 to 72 h.
Meta-analysis. Data on the primary treatment response rate,
lesion size, and treatment duration from the 21 trials and the one
secondary analysis deemed eligible for the meta-analysis are sum-
marized in Table 2.
(i) Treatment response at the TOC endpoint. The four proxy
for placebo uSSTI trials reported TOC clinical treatment response
rates ranging from 8% to 66% (Table 2) (35–38). Clinical and
methodological heterogeneity was evident for lesion size, infec-
tion type, and timing of the TOC assessment (Table 3). For the
meta-analysis, the trial that restricted enrollment to subjects with
SITL was excluded (35), resulting in a pooled proxy for placebo
TOC clinical treatment response rate of 31.0% (95% CI, 6.2% to
FIG 1 Flow chart depicting the systematic literature search for trials of treatment effect estimation in acute bacterial skin and skin structure infection (ABSSSI):
publication identification, screening, eligibility, and trial inclusion. RCT, randomized clinical trial.
Cates et al.
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55.9%); the variance across trials (I2  90.6%, P  0.0001) was
high (Fig. 2a) (36–38). Eleven of the 12 linezolid trials reported
TOC clinical treatment response rates ranging from 50% to 95%
(Table 2) (39–44, 46–50). These trials, published over a 13-year
interval, had evidence of clinical and methodological heterogene-
ity for lesion size, type of infection, geographic region, MRSA
etiology, per-protocol treatment duration, definition of clinical
success, and timing of TOC assessment (Tables 2 and 3). For the
meta-analysis, the selection of the three linezolid trials com-
prised subjects with total surface area lesion size of 75 cm2,
non-MRSA-specific populations, and 50% of subjects with
abscesses (39, 41, 42). The pooled linezolid TOC clinical treat-
ment response rate was 88.1% (95% CI, 81.0% to 95.1%) (Fig.
2b), with evidence of variation across the trials (I2  80.4, P 
0·006). The three ceftaroline trials had consistent distributions
of infection types, durations of treatment, definitions of clini-
cal success, and timing of TOC assessment (Tables 2 and 3).
The pooled ceftaroline TOC clinical treatment response rate
was 86.1% (95% CI, 83.7% to 88.6%) (Fig. 2c), with no evi-
dence of clinical, methodological, and statistical heterogeneity
(I2  0, P  0.74) (51–53). The TOC endpoint was not reported
in the trials of UV light (23, 24).
(ii) Treatment response at the early clinical endpoint. No
early clinical treatment response was reported in the proxy for
placebo uSSTI trials. The early clinical treatment response for li-
nezolid in the ITT population was reported in three trials, with a
pooled estimate of 78.7% (95% CI, 61.1% to 96.3%); a high vari-
ance across trials (I2  96.7%, P  0·0001) was evident (39, 41,
42). This response rate approximated the early clinical treatment
response rate of 79.4% (95% CI, 75.1% to 83.7%) reported in the
most robust of the three linezolid trials with these data, as well as
the early clinical treatment response of ceftaroline at 74.0% (95%
CI, 69.7% to 78.3%) reported in one trial (39, 54). The pooled UV
light treatment response in erysipelas at the early endpoint was
59.0% (95% CI, 52.8% to 65.3%), with low variance between the
two trials (I2  0, P  0.482), as well as low methodological and
TABLE 1 Study design, population, and active comparator of 22 published trials identified in a systematic review for antibacterial treatment effect
estimation for acute bacterial skin and skin structure infectionsa
Treatment and study Trial and designb Population age and infection typec Comparator
Placebo in uncomplicated SSTI, n  4
Tomayko et al., 2013 (35) Phase 3, RCT, DB Age 9 mo with SITL Topical retapamulin
Koning et al., 2008 (36) RCT, DB Age 9 mo with impetigo Topical retapamulin
Colin and Avon, 1988 (37) RCT, DB Subjects with SSTI Topical mupirocin
Zaynoun et al., 1974 (38) RCT, DB Age 4 mo with pyodermad Topical gentamicin
Linezolid, n  12
Prokocimer et al., 2013 (39) Phase 3, RCT, DB Adults with ABSSSI Tedizolid
Noel et al., 2012 (40) Phase 2, RCT, EB phase 2,
RCT, EB
Age 18 yr with cSSSI Omadacycline
Covington et al., 2011 (41) Phase 2, RCT, EB Age 18 yr with ABSSSI JNJ-QR
Craft et al., 2011 (42) Phase 2, RCT, EB Age 18 yr with ABSSSI CEM-102
Lin et al., 2008 (43) Phase 3, RCT, DB Age 18 yr in China with cSSTI or
pneumonia
Vancomycin
Kohno et al., 2007 (44) RCT, OL Adults in Japan with cSSTI, pneumonia, or
sepsis due to MRSA
Vancomycin
Jauregui et al., 2005 (45) Phase 3, RCT, DB Adults with cSSSI Dalbavancin
Sharpe et al., 2005 (46) RCT, OL Age 18 yr with MRSA cSSTI Vancomycin
Weigelt et al., 2005 (47) RCT, OL Adults with MRSA cSSTI Vancomycin
Chen et al., 2004 (48) One arm, OL Adults with cSSTI in the Asia-Pacific
region
No comparator
Stevens et al., 2002 (49) RCT, OL Age 13 yr with MRSA cSSTI,
pneumonia, UTI, or bacteremia
Vancomycin
Stevens et al., 2000 (50) RCT, DB Age 18 yr with cSSTI Oxacillin-dicloxacillin
Ceftaroline, n  4
Friedland et al., 2012 (54) Secondary analysis phase 3
RCT, DB
Adults with ABSSSI Vancomycin
Corey et al., 2010 (51) Phase 3, RCT, DB Age 18 yr with cSSSI Vancomycin
Wilcox et al., 2010 (52) Phase 3, RCT, DB Age 18 yr with cSSSI Vancomycin
Talbot et al., 2007 (53) Phase 2, RCT, EB Age 18 yr with cSSSI Vancomycin
UV light, n  2
Snodgrass and Anderson, 1937 (23) Clinical, OL Subjects with erysipelas Prontosil
Snodgrass and Anderson, 1937 (24) Clinical, OL Subjects with erysipelas Sulfanilamide
a Intention-to-treat population assigned to linezolid, ceftaroline, placebo, or UV light for complicated skin and soft tissue infections (cSSTI), complicated skin and skin structure
infections (cSSSI), or acute bacterial skin and skin structure infections (ABSSSI).
b RCT, randomized control trial; DB, double blinded; EB, evaluator blinded; OL, open label.
c Geographic region mentioned where relevant. SITL, secondarily infected traumatic lesion; MRSA, methicillin-resistant Staphylococcus aureus; UTI, urinary tract infection.
d Infections were impetigo, insect bites, and dermatitis.
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clinical heterogeneity in the trial design or execution (Tables 2 and
3) (23, 24).
Antibacterial treatment effect estimation for ABSSSI. Given
the biological plausibility of UV light treatment against bacteria,
the response rates to UV light treatment in erysipelas were consid-
ered inappropriate as proxy for placebo responses (23, 24, 55).
Given no available proxy for placebo early clinical treatment re-
sponse data, an early clinical treatment effect estimate could not
be calculated for linezolid or ceftaroline. In contrast, the available
proxy for placebo uSSTI treatment response rate (31.0%; 95% CI,
6.2% and 55.9%) permitted calculation of the TOC clinical treat-
ment effect estimate for linezolid and ceftaroline. This across-
trials comparison, defined as the difference between the upper
bound of the 95% CI for the proxy for placebo treatment response
and the respective lower bound of the 95% CI for the treatment
response in linezolid (81.0%) and in ceftaroline (83.7%), resulted
in TOC clinical treatment effect estimation of 25.1% for linezolid
and 27.8% for ceftaroline (Table 4).
Risk of bias assessment. From the assessment of publication
quality and risk of bias, the four placebo-controlled trials of uSSTI
all had low or uncertain bias scores, 7 of the 16 active comparator
trials had one or more high bias scores, and the 2 nonantibacterial
trials of UV light had high bias in three of the six categories (Table
5). Funnel plots were assessed (data not shown) to determine po-
tential publication bias; however, the assessment was inconclu-
sive, given the small number of trials and the heterogeneity in
treatment response rates.
DISCUSSION
The findings from this systematic review and meta-analysis of the
antibacterial treatment effect estimation in ABSSSI inform on fu-
ture trial designs for this group of infections. The early clinical
TABLE 2 Trial parameters and treatment response estimates for placebo treatment in uncomplicated skin and soft tissue infection and antibacterial
and nonantibacterial treatment for acute bacterial skin and skin structure infection
Treatment and study Skin infection lesion size





Placebo in uncomplicated SSTI, n  4
Tomayko et al., 2013 (35) Total area 100 cm2 NAb NA 75/113 (66.4)
Koning et al., 2008 (36) Total area 100 cm2 NA NA 28/71 (39.4)
Colin and Avon, 1988 (37) Subgroups: 1–2, 2–4,
4–6, 6 cm2
NA NA 2/25 (8.0)
Zaynoun et al., 1974 (38) NA NA NA 12/25 (48.0)
Linezolid, n  12
Prokocimer et al., 2013 (39) 75 cm2 NA 266/335 (79.4) 288/335 (86.0)
Noel et al., 2012 (40) 13.5 cm (14.2)c 9.6 (4.4) NA 82/108 (75.9)
Covington et al., 2011 (41) 75 cm2 NA 45/78 (57.7) 64/78 (82.1)
Craft et al., 2011 (42) 100 cm2 11.5 (NA) 63/65 (97) 73/77 (94.8)
Lin et al., 2008 (43) NA 12.2 (5.4) NA 30/33 (90.9)
Kohno et al., 2007 (44) NA 10.9 (5.0) NA 9/17 (52.9)d
Jauregui et al., 2005 (45) NA NA NA NAe
Sharpe et al., 2005 (46) NA NA NA 15/30 (50.0)d
Weigelt et al., 2005 (47) NA 11.8 (4.9) NA 439/583 (75.3)
Chen et al., 2004 (48) NA NA NA 72/77 (93.5)
Stevens et al., 2002 (49) 51.2% with lesions 28
cm2
12.6 (7.1) NA 37/53 (69.8)d
Stevens et al., 2000 (50) NA 13.4 (5.4) NA 279/400 (69.8)
Ceftaroline, n  4
Friedland et al., 2012 (54) 75 cm2 NA 296/400 (74·0) NA
Corey et al., 2010 (51) 83.5% had 1
dimension 5 cm
Median, 7 NA 304/351 (86.6)
Wilcox et al., 2010 (52) 94.3% had 1
dimension 5 cm
Median, 6.5 NA 291/342 (85.1)
Talbot et al., 2007 (53) NA Median, 7.8 (range, 0.4–19.5) NA 59/67 (88.1)
UV light, n  2
Snodgrass and Anderson, 1937 (23) NA 2.6 exposuresf 64/104 (61.5) NA
Snodgrass and Anderson, 1937 (24) NA 1.4 exposuresf 77/135 (57.0) NA
a Values are mean (SD) unless otherwise specified. Rx, treatment.
b NA, not available.
c Mean maximum linear dimension (SD).
d Microbiological ITT (MITT) reported for Sharpe et al., 2005 (46), and Stevens et al., 2002 (49), but microbiological evaluable (ME) was the only outcome available in Kohno et
al., 2007 (44).
e Jauregui et al., 2005 (45), report results for the clinically evaluable (CE) and microbiological evaluable (ME) population at TOC.
f Exposures per case.
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treatment responses for linezolid (78.7%), ceftaroline (74.0%),
and UV light (59.0%), provide reference data for the recently rec-
ommended primary endpoint in ABSSSI trials (9). The TOC treat-
ment effect estimations for linezolid (25.1%) and ceftaroline
(27.8%) provide historical data for noninferiority margin justifi-
cation in future noninferiority trial designs and for superiority
trial designs that may include adaptive models and futility stop-
ping criteria (56, 57). Overall, our findings provide historical evi-
dence of the sensitivity to drug effect (HESDE) at the TOC end-
point for ABSSSI and are consistent with prior estimations of the
treatment effect (13).
These TOC treatment effect estimations are conservative, yet
are based on the calculations recommended in the FDA guidance
(9). These estimates are conservative for two reasons. First, the
definition of the antibacterial treatment effect as the difference
between the upper bound of the 95% CI for the proxy for placebo
treatment response and the respective lower bound of the 95% CI
for the antibacterial treatment response is intrinsically conserva-
tive. An alternative calculation based on the difference in the point
estimates of the placebo and treatment group response rates
would yield treatment effect estimations of 57.1% for linezolid
and 55.1% for ceftaroline (Table 4). Second, these estimates are
further conservative, given that the placebo treatment response
for uSSTI, assumed to be higher than the placebo treatment re-
sponse in ABSSSI, was used as a proxy for the placebo response in
ABSSSI. As in most antibacterial trials involving serious infection
indications, where there is existing effective therapy as the stan-
dard of care, placebo treatment is medically and ethically inappro-
priate and historically not reported. Hence, randomized, parallel-
group noninferiority trials are employed to demonstrate drug
efficacy and meet the regulatory guidance for approval of a new
test or antibacterial agent in serious infection indications (7–9,
12). To inform on noninferiority margins, we followed the FDA
guidance for use of a proxy for placebo in the absence of a true
placebo response for ABSSSI. While the placebo response rate in
uSSTI should not be interpreted as the true placebo response rate
FIG 2 Forest plots of the primary meta-analysis for clinical response at test of cure for proxy-for-placebo treatment (a), linezolid treatment (b), and ceftaroline
treatment (c). RE, random effects.
TABLE 4 Summary of meta-analysis results for the clinical treatment response at the test-of-cure endpoint for placebo in uncomplicated skin and
soft tissue infection, linezolid, and ceftaroline, and estimated antibacterial treatment effect estimation for acute bacterial skin and skin structure
infection
Treatment group (no. of
trials)a
Point estimate response





Placebo in uSSTI (3) 31.0 (6.2–55.9)
Linezolid in ABSSSI (3) 88.1 (81.0–95.1) 25.1 57.1
Ceftaroline in ABSSSI (3) 86.1 (83.7–88.6) 27.8 55.1
a uSSTI, uncomplicated skin and soft tissue infection; ABSSSI, acute bacterial skin and skin structure infection.
b CI, confidence interval.
c Calculated as the difference between the lower bound of the 95% CI of the response rate estimate for each antibacterial treatment and the upper bound of the 95% CI of the proxy
for placebo response rate estimate (13, 20).
d Calculated as the difference in the point estimate of the response rate between each antibacterial treatment and placebo.
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in ABSSSI, we assumed that the use of this proxy for the placebo
treatment response, resulting in an overestimation of the ABSSSI
placebo treatment response, is a conservative approach in estimat-
ing antibacterial efficacy relative to that of placebo. Based on the
uncertainty of the true placebo effect and the use of the FDA
guidance, each ABSSSI treatment effect estimate is conservative,
given that the overestimation of the ABSSSI placebo treatment
response results in a conservative underestimation of the ABSSSI
treatment effect (14, 22, 58).
The second major finding from our study is the evidence and
assessment of heterogeneity in these historical clinical trials as
relevant and informative to future ABSSSI clinical trials. For the
meta-analysis, all data from the ceftaroline trials were included,
given minimal evidence for clinical, methodological, and statisti-
cal heterogeneity. For the linezolid trials, data from the maximum
number of trials (n  12) offered the potential benefit of increased
robustness for the treatment effect estimate, but this was offset by
significant evidence of clinical, methodological, and statistical
heterogeneity (31). The meta-analysis trial selection process for
the linezolid TOC clinical treatment response was prioritized to
identify the historical trials aligned with the recent FDA regulatory
guidance for future ABSSSI trials. This process yielded a selection
of just three trials and represented the best reproducibility for the
linezolid treatment response to be observed in future noninferi-
ority trials, along with the potential to minimize the deviations in
the study operating characteristics, inclusive of type I error and
power.
As with all systematic reviews and meta-analyses, we acknowl-
edge the potential bias inherent in our study design and reported
findings. First, the publications identified in the systematic review
were contingent upon the search terms used, and the inclusion of
open-label studies may have introduced bias to the reported out-
comes of effectiveness (59). Second, other active comparator
treatment effect estimations are plausible for ABSSSI and can be
assessed in future meta-analyses. Tedizolid, as an example, was in
late-stage development for ABSSSI during the conduct of our sys-
tematic review and meta-analysis. Active comparator data for the
linezolid treatment response, from the tedizolid phase 3 trial, was
included in our meta-analysis (Fig. 2b), and a recent safety sum-
mary of tedizolid suggests supportive evidence of preclinical and
clinical data for tedizolid treatment in ABSSSI (39, 60). Given the
recent approval for use of tedizolid in ABSSSI, the tedizolid treat-
ment effect estimation can be systematically examined for future
trials that utilize tedizolid as the active comparator agent. Third,
debate continues for the primary endpoint measures in ABSSSI
clinical trials (9–11, 13, 15, 16, 20, 60–63). In alignment with the
TABLE 5 Assessment of publication bias in 22 publications of placebo treatment for uncomplicated skin and soft tissue infection and antibacterial
















Placebo in uncomplicated SSTI, n  4
Tomayko et al., 2013 (35) L L L L U U
Koning et al., 2008 (36) U U L L U U
Colin and Avon, 1988 (37) U U L L U U
Zaynoun et al., 1974 (38) U L L L U U
Linezolid, n  12
Prokocimer et al., 2013 (39) L L L L L U
Noel et al., 2012 (40) L L L L U U
Covington et al., 2011 (41) U U L L U U
Craft et al., 2011 (42) U L L U U U
Lin et al., 2008 (43) U U L U U U
Kohno et al., 2007 (44) U H H L L U
Jauregui et al., 2005 (45) L L L L H U
Sharpe et al., 2005 (46) U H H L L U
Weigelt et al., 2005 (47) U H H U U U
Chen et al., 2004 (48) H H H L L U
Stevens et al., 2002 (49) U H H L U U
Stevens et al., 2000 (50) U L L L U U
Ceftaroline, n  4
Friedland et al., 2012 (54) L L L L L U
Corey et al., 2010 (51) L L L L U U
Wilcox et al., 2010 (52) L L L L U U
Talbot et al., 2007 (53) U L Hc L U U
UV light, n  2
Snodgrass and Anderson, 1937 (23) H H H L U U
Snodgrass and Anderson, 1937 (24) H H H L U U
a Cochrane Risk of Bias Tool and PRISMA guidelines. H, high bias; U, uncertain bias or unable to determine; L, low bias.
b Blinding of participants, personnel, and outcome assessment.
c Evaluator blinded only.
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regulatory guidance, we have categorized the early clinical treat-
ment response at 48 to 72 h, when available, as well as the TOC
clinical treatment response, when available. Both the timing of the
TOC endpoint and the characterization of the clinical treatment
response at this endpoint were limited by nonstandardized defi-
nitions across studies (Table 3). Fourth, the early outcome mea-
sure for ABSSSI recommended by the Foundation of the National
Institutes of Health, of at least 20% reduction in total surface area
at day 2 or day 3 versus baseline was not definitely reported in the
trials that met our final inclusion criteria, and, therefore, ces-
sation of spread at 48 to 72 h was substituted for this endpoint
(20, 62, 63). The comparative early endpoint analysis for ces-
sation of spread versus at least 20% reduction in total surface
areas was, therefore, beyond the scope of our systematic review.
Fifth, only three linezolid studies and one ceftaroline study
reported the 48- to 72-h early clinical treatment response, and,
hence, the small sample size affects the robustness of this mea-
sure of treatment response. Sixth, it is plausible that successful
early clinical treatment responses in ABSSSI subjects (48 to 72
h) might potentially become failures at later efficacy time point
measurements (7 to 14 days posttreatment). Future clinical
trials and nonrandomized studies are needed to assess subjects
at both early and later endpoints, in order to further under-
stand the potential discordances between early successes and
late failures and subsequent clinical implications (39, 45). Sev-
enth, publication bias may exist, but assessment using funnel
plot analysis was inconclusive for such bias. Last, we acknowl-
edge potential secular changes in the standard of medical care
and hygiene practices, which may have influenced treatment
effect estimates from these historical studies.
In summary, the results of this systematic review and meta-
analysis for the antibacterial treatment effect estimation for
ABSSSI inform the design, execution, and analysis of future
ABSSSI trials. The across-trials comparison enables noninferi-
ority margin justification in the absence of placebo-controlled
trials for ABSSSI. We have characterized the vast amount of
clinical, methodological, and statistical heterogeneity for
ABSSSI as reported in trials of proxy for placebo treatment as well
as trials of linezolid and ceftaroline.
APPENDIX
Search terms for the systematic review for antibacterial treatment
effect estimation for acute bacterial skin and skin structure infec-
tion. Publications were restricted to dates before 28 February 2013.
Searches included abbreviations, plural, and full-phrase versions of
the terms.
Search A1. For placebo-controlled trials for ABSSSI, the search
terms were “placebo” combined with “SSTI,” “SSSI,” “ABSSSI,”
“cellulitis,” “abscess,” “wound infection,” “burn infection,” and
“erysipelas.”
Search A2. For uSSTI publications, the search terms were “pla-
cebo” combined with “SSTI,” “SSSI,” “ABSSSI,” “impetigo,” “ab-
scess,” “cellulitis,” “furunculosis,” “carbunculosis,” “folliculitis,”
“traumatic lesion,” “erysipelas,” and “ecthyma.”
Searches B1 and B2. The searches for linezolid and ceftaroline
were conducted separately, with each drug name, respectively,
combined with “SSTI,” “SSSI,” “ABSSSI,” “cellulitis,” “abscess,”
“wound infection,” “burn infection,” and “erysipelas.”
Search C. For trials reporting nonantibacterial treatment re-
sponse, the terms included all previously listed skin infection
terms, along with a review of the available reports of nonantibac-
terial treatment in skin infections.
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